Tenax Therapeutics Inc. (TENX) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, TENX carries an RQD Score of 39 out of 100, a letter grade of D-, and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 3 / 20. The rating cites ROIC of -35% and an FCF yield of 0%. For a prospective investor, this means the business is not currently generating returns on capital or free cash flow. Any upside case must rest on future events rather than present earnings power.
• Whale 13F Flow: 9 / 20. The rating characterizes this pillar as "Institutional accumulation & options positioning." Institutional activity is present, but it scores below the midpoint and should be weighed against the fundamental weakness above.
• Insider Conviction: 5 / 20. The rating references "SEC Form 4 & Congressional PTR cluster flow." This is a weak score, indicating limited insider-driven confidence signals in the source data.
• Macro Regime Fit: 15 / 20. Per the rating, beta is 1.0 with "sector sensitivity." This is the strongest pillar, but it reflects market-sensitivity characteristics rather than company-specific strength.
• Forensic Balance Sheet: 7 / 20. The rating cites Altman Z 0.23, Piotroski F 2/9, and Debt/Equity 0.5. These readings point to financial distress indicators and weak fundamental health.

Taken together, the rating frames TENX as a high-risk setup where valuation tradeoffs are dominated by balance-sheet vulnerability and negative operating returns. Any prospective investor evaluating the stock should treat the cash position and burn rate as the central variables, since the source data shows operating losses and negative free cash flow across all reported periods.

Per the SEC financials, operating losses widened from $-8.2M in FY 2023 to $-56.4M in FY 2025, and net losses followed the same trajectory. Per the market data, gross, operating, and net margins are each reported as 0%, and ROIC is -35%. The rating cites an Altman Z-Score of 0.23 and a Piotroski F-Score of 2/9. Reported cash was $97.6M at FY 2025 versus $94.9M at FY 2024, while FCF was $-35.8M in FY 2025, and debt is listed as N/A in every period.

• Cautious analyst commentary (RISK WATCH, RED): A Yahoo Finance headline references a cautious analyst call on LEVEL data and a fair-value decline for TENX.
• Phase 3 trial failure and litigation inquiry (MARKET WIRE, YELLOW): A mykxlg.com headline states that Johnson Fistel is investigating potential securities law violations after a Phase 3 trial failure, with shares reported to have plummeted nearly 90%. This is the most material negative catalyst in the feed.
• Institutional accumulation (MARKET WIRE, YELLOW): A GuruFocus headline reports that SPHERA FUNDS MANAGEMENT LTD. boosted its TENX stake with a 669,800-share purchase.
• Holder filings (MARKET WIRE, YELLOW): A Stock Titan headline reports three parties each holding 1.36M shares of TENX.
• Forecast and estimates coverage (MARKET WIRE, YELLOW): StockInvest.us and TradingView headlines cover price forecasts and estimates without quantified content in the source data.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as "NONE," with no butterfly links and no proprietary signals.

• What was the Phase 3 trial that reportedly failed, and what is the current development pipeline status?
• What revenue, product, or licensing model, if any, does the company have, given $0.0M reported revenue in every period?
• What is the company's cash runway at the FY 2025 burn rate of $-35.8M, and what financing or debt arrangements exist, since debt is listed as N/A?
• What is the basis for the reported cautious analyst view on LEVEL data, and what are the associated fair-value estimates?
• What insider, 13F, and Congressional holdings and trades apply to TENX, given that the holders and analyst data sections are empty?